Autonomix Medical Inc (AMIX) Q2 2025 Earnings Report

Autonomix Medical reported a continued negative bottom line in QQ2 2025, underscoring the company’s status as an early-stage developer in the medical device space. R&D and G&A expenses totaled $2.836 million, driving EBITDA of -$2.719 million and an operating loss of -$2.836 million. The company disclosed no revenue for the quarter, suggesting the burn is being funded by existing liquidity rather than operating cash flow. Cash at the period end was $5.156 million, with total liabilities of $2.343 million and long-term debt of $1.086 million, resulting in a net cash position of approximately $4.069 million and a solid current ratio of 4.26. Net cash burn from operating activities was -$1.596 million for QQ2 2025, implying a remaining cash runway that will hinge on successful clinical validation, regulatory progress, or strategic partnerships to monetize the technology. On a YoY basis, operating income declined sharply by -124.54% (driven by the same negative profitability trajectory), while net income improved by 53.53% year over year and earnings per share (EPS) improved by 56.82% YoY, though the quarter still posted an EPS of -$2.47. Given the lack of disclosed revenue and the ongoing funding requirements, the stock remains highly speculative with value contingent on future milestones in the peripheral nervous system sensing platform and potential commercialization opportunities.